Surrozen, Inc. Common (SRZN)
Surrozen, Inc. is a biotechnology company focused on developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases. It leverages its proprietary SUREkill platform to discover and develop antibody-based medicines aimed at modulating the immune system and improving patient outcomes.
Company News
Biotechnology company Surrozen reported a surprising Q2 2025 net income of $39.7 million, driven primarily by non-cash gains, while continuing to advance its ophthalmology pipeline focused on Wnt pathway modulation.
Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results. Capri Holdings Limited (NYSE: CPRI) climbed 56.1% to $54.03 after Tapestry announced a definitive agreement to acquire the company. Blend Labs, Inc. (NYSE: BLND) rose 32% to $1.6198 f...
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.